As a full-service CRO for early clinical trials in diabetes and obesity, Profil has brought together regulatory and scientific experts so that we can offer you unrivalled service. We focus that expertise on developing sophisticated experimental methods, optimizing study designs, and delivering critical answers for further compound development. Profil began life as a spin-off of an academic study group at the Department of Metabolic Diseases and Nutrition at the University of Düsseldorf. Our founders wished to create a dedicated CRO that would address the challenges of diabetes and obesity research and treatment. The company’s achievements are testament to that vision. Over the years, we have implemented numerous sophisticated methods for pharmacodynamic characterization of the effects of compounds in early phase trials, and we have been involved in the development of all the currently available major anti-diabetic compounds. Our key competence is the performance of glucose clamp studies, often combined with isotope dilution techniques and muscle or fat biopsies.